Tolerogenic nanotherapy for type 1 diabetes via targeted rapamycin delivery
A cell-selective nanotherapy that reroutes rapamycin to antigen-presenting cells, inducing long-lived immune tolerance instead of temporary immunosuppression. Validated in murine islet transplant models, the platform is ...